S&P 500
$5,842.01
-0.0%
-$2.60
DJI
41,859.09
-0.0%
-1.35
NASDAQ
$18,925.73
+0.3%
+$53.09
Bitcoin
110,972.00
+0.5%
+552.88
AAPL
$201.16
-0.5%
-$0.93
AMZN
$202.96
+0.9%
+$1.84
GOOG
$171.96
+1.1%
+$1.90
META
$636.81
+0.2%
+$1.31
MSFT
$454.60
+0.4%
+$2.03
NVDA
$132.90
+0.8%
+$1.10
TSLA
$341.59
+2.1%
+$6.97
Cabaletta Bio (NASDAQ: CABA)
$1.78
(-1.1%)
-$0.02
Price as of May 22, 2025, 3:58 p.m. ET
Cabaletta Bio Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Cabaletta Bio Company Info
Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.
News & Analysis
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.